Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

6. december 2012 opdateret af: Pfizer

Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS

This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

795

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Australien
    • New South Wales
      • Campsie, New South Wales, Australien, 2194
        • Pfizer Investigational Site
    • Queensland
      • Cairns, Queensland, Australien, 4870
        • Pfizer Investigational Site
      • Maroochydore, Queensland, Australien, 4558
        • Pfizer Investigational Site
    • South Australia
      • Woodville, South Australia, Australien, 5011
        • Pfizer Investigational Site
    • Victoria
      • Malvern East, Victoria, Australien, 3145
        • Pfizer Investigational Site
    • Western Australia
      • Shenton Park, Western Australia, Australien, 6008
        • Pfizer Investigational Site
  • Chile
      • Vina del Mar, Chile, 2570017
        • Pfizer Investigational Site
    • RM
      • Santiago, RM, Chile, 7510186
        • Pfizer Investigational Site
      • Santiago, RM, Chile, 8360156
        • Pfizer Investigational Site
    • Santiago, RM
      • Providencia, Santiago, RM, Chile, 7530206
        • Pfizer Investigational Site
    • V Region
      • Vina del Mar, V Region, Chile, 2570017
        • Pfizer Investigational Site
  • Colombia
    • Atlantico
      • Barranquilla, Atlantico, Colombia, 0000
        • Pfizer Investigational Site
    • Cundinamarca
      • Bogota, Cundinamarca, Colombia
        • Pfizer Investigational Site
    • Santander
      • Bucaramanga, Santander, Colombia
        • Pfizer Investigational Site
  • Danmark
      • Frederiksberg, Danmark, 2000
        • Pfizer Investigational Site
  • Den Russiske Føderation
      • Moscow, Den Russiske Føderation, 115093
        • Pfizer Investigational Site
      • Moscow, Den Russiske Føderation, 115446
        • Pfizer Investigational Site
      • Petrozavodsk, Den Russiske Føderation, 185019
        • Pfizer Investigational Site
  • Det Forenede Kongerige
      • Newcastle Upon Tyne, Det Forenede Kongerige, NE1 4LP
        • Pfizer Investigational Site
    • Merseyside
      • Wirral, Merseyside, Det Forenede Kongerige, CH49 5PE
        • Pfizer Investigational Site
    • Staffs
      • Cannock, Staffs, Det Forenede Kongerige, WS11 2XY
        • Pfizer Investigational Site
    • West Midlands
      • Solihull, West Midlands, Det Forenede Kongerige, B91 2JL
        • Pfizer Investigational Site
  • Finland
      • Helsinki, Finland, 00120
        • Pfizer Investigational Site
      • Hyvinkaa, Finland, 05800
        • Pfizer Investigational Site
      • Tampere, Finland, 33520
        • Pfizer Investigational Site
  • Forenede Stater
    • Alabama
      • Huntsville, Alabama, Forenede Stater, 35801
        • Pfizer Investigational Site
    • Arkansas
      • Jonesboro, Arkansas, Forenede Stater, 72401
        • Pfizer Investigational Site
    • California
      • Palo Alto, California, Forenede Stater, 94304
        • Pfizer Investigational Site
      • Stanford, California, Forenede Stater, 94305
        • Pfizer Investigational Site
    • Colorado
      • Boulder, Colorado, Forenede Stater, 80304
        • Pfizer Investigational Site
      • Denver, Colorado, Forenede Stater, 80206
        • Pfizer Investigational Site
    • Connecticut
      • Danbury, Connecticut, Forenede Stater, 06810
        • Pfizer Investigational Site
      • Hamden, Connecticut, Forenede Stater, 06518
        • Pfizer Investigational Site
      • Trumbull, Connecticut, Forenede Stater, 06611
        • Pfizer Investigational Site
    • Florida
      • New Port Richey, Florida, Forenede Stater, 34652
        • Pfizer Investigational Site
      • Ocala, Florida, Forenede Stater, 34474
        • Pfizer Investigational Site
      • Plantation, Florida, Forenede Stater, 33324
        • Pfizer Investigational Site
      • Port Richey, Florida, Forenede Stater, 34668
        • Pfizer Investigational Site
      • Tamarac, Florida, Forenede Stater, 33321
        • Pfizer Investigational Site
      • Tampa, Florida, Forenede Stater, 33613
        • Pfizer Investigational Site
    • Georgia
      • Decatur, Georgia, Forenede Stater, 30033
        • Pfizer Investigational Site
      • Marietta, Georgia, Forenede Stater, 30060
        • Pfizer Investigational Site
    • Illinois
      • Maywood, Illinois, Forenede Stater, 60153
        • Pfizer Investigational Site
      • Oakbrook Terrace, Illinois, Forenede Stater, 60181
        • Pfizer Investigational Site
      • Rockford, Illinois, Forenede Stater, 61103-3692
        • Pfizer Investigational Site
      • Springfield, Illinois, Forenede Stater, 62702
        • Pfizer Investigational Site
      • Springfield, Illinois, Forenede Stater, 62703
        • Pfizer Investigational Site
      • Vernon Hills, Illinois, Forenede Stater, 60061
        • Pfizer Investigational Site
    • Indiana
      • Evansville, Indiana, Forenede Stater, 47714
        • Pfizer Investigational Site
      • Indianapolis, Indiana, Forenede Stater, 46227
        • Pfizer Investigational Site
    • Kansas
      • Wichita, Kansas, Forenede Stater, 67203
        • Pfizer Investigational Site
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40505
        • Pfizer Investigational Site
    • Massachusetts
      • Leominster, Massachusetts, Forenede Stater, 01453
        • Pfizer Investigational Site
      • Worcester, Massachusetts, Forenede Stater, 01605
        • Pfizer Investigational Site
    • Minnesota
      • Edina, Minnesota, Forenede Stater, 55435
        • Pfizer Investigational Site
    • Nebraska
      • Lincoln, Nebraska, Forenede Stater, 68516
        • Pfizer Investigational Site
    • New York
      • Albany, New York, Forenede Stater, 12206
        • Pfizer Investigational Site
      • Orchard Park, New York, Forenede Stater, 14127
        • Pfizer Investigational Site
      • Rochester, New York, Forenede Stater, 14618
        • Pfizer Investigational Site
    • North Carolina
      • Asheville, North Carolina, Forenede Stater, 28801
        • Pfizer Investigational Site
      • Charlotte, North Carolina, Forenede Stater, 28210
        • Pfizer Investigational Site
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forenede Stater, 18015
        • Pfizer Investigational Site
      • Wyomissing, Pennsylvania, Forenede Stater, 19610
        • Pfizer Investigational Site
    • South Carolina
      • Greenville, South Carolina, Forenede Stater, 29601
        • Pfizer Investigational Site
    • Tennessee
      • Knoxville, Tennessee, Forenede Stater, 37909
        • Pfizer Investigational Site
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • Pfizer Investigational Site
      • Dallas, Texas, Forenede Stater, 75235
        • Pfizer Investigational Site
    • Washington
      • Seattle, Washington, Forenede Stater, 98133
        • Pfizer Investigational Site
      • Tacoma, Washington, Forenede Stater, 98405
        • Pfizer Investigational Site
      • Tacoma, Washington, Forenede Stater, 98405-2308
        • Pfizer Investigational Site
    • West Virginia
      • Clarksburg, West Virginia, Forenede Stater, 26301
        • Pfizer Investigational Site
  • Grækenland
      • Maroussi Athens, Grækenland, 15126
        • Pfizer Investigational Site
  • Kina
      • Beijing, Kina, 100853
        • Pfizer Investigational Site
      • Beijing, Kina, 100020
        • Pfizer Investigational Site
      • Beijing, Kina, 100044
        • Pfizer Investigational Site
      • Shanghai, Kina, 200001
        • Pfizer Investigational Site
      • Shanghai, Kina, 200433
        • Pfizer Investigational Site
      • Shanghai, Kina, 200003
        • Pfizer Investigational Site
      • Tianjin, Kina, 300052
        • Pfizer Investigational Site
    • Anhui
      • Hefei, Anhui, Kina, 230022
        • Pfizer Investigational Site
      • Hefei, Anhui, Kina, 230001
        • Pfizer Investigational Site
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510630
        • Pfizer Investigational Site
      • Guangzhou, Guangdong, Kina, 510260
        • Pfizer Investigational Site
    • Hubei
      • Wuhan, Hubei, Kina, 430030
        • Pfizer Investigational Site
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Pfizer Investigational Site
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • Pfizer Investigational Site
      • Suzhou, Jiangsu, Kina, 215006
        • Pfizer Investigational Site
    • Shandong
      • Jinan, Shandong, Kina, 250012
        • Pfizer Investigational Site
      • Qingdao, Shandong, Kina, 266011
        • Pfizer Investigational Site
    • Shanxi
      • Xi'an, Shanxi, Kina, 710032
        • Pfizer Investigational Site
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Pfizer Investigational Site
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310009
        • Pfizer Investigational Site
  • Kroatien
      • Opatija, Kroatien, 51410
        • Pfizer Investigational Site
      • Zagreb, Kroatien, 10000
        • Pfizer Investigational Site
  • Malaysia
    • Negeri Sembilan
      • Seremban, Negeri Sembilan, Malaysia, 70300
        • Pfizer Investigational Site
    • Selangor
      • Batu Caves, Selangor, Malaysia, 68100
        • Pfizer Investigational Site
      • Subang Jaya, Selangor, Malaysia, 47500
        • Pfizer Investigational Site
    • Wilayah Persekutuan
      • Putrajaya, Wilayah Persekutuan, Malaysia, 62250
        • Pfizer Investigational Site
  • Mexico
    • Coahuila
      • Torreon, Coahuila, Mexico, 27000
        • Pfizer Investigational Site
    • Michoacan
      • Morelia, Michoacan, Mexico, 58249
        • Pfizer Investigational Site
    • Morelos
      • Cuernavaca, Morelos, Mexico, 62270
        • Pfizer Investigational Site
    • Queretaro
      • Mexico, Queretaro, Mexico, 76178
        • Pfizer Investigational Site
    • Yucatan
      • Merida, Yucatan, Mexico, 97000
        • Pfizer Investigational Site
  • Polen
      • Bialystok, Polen, 15-337
        • Pfizer Investigational Site
      • Bialystok, Polen, 15-461
        • Pfizer Investigational Site
      • Koscian, Polen, 64-000
        • Pfizer Investigational Site
      • Poznan, Polen, 60-773
        • Pfizer Investigational Site
      • Torun, Polen, 87-100
        • Pfizer Investigational Site
  • Slovakiet
      • Nove Zamky, Slovakiet, 94001
        • Pfizer Investigational Site
      • Poprad, Slovakiet, 058 01
        • Pfizer Investigational Site
      • Povazska Bystrica, Slovakiet, 017 01
        • Pfizer Investigational Site
      • Rimavska Sobota, Slovakiet, 979 01
        • Pfizer Investigational Site
      • Senica, Slovakiet, 905 01
        • Pfizer Investigational Site
      • Zilina, Slovakiet, 010 01
        • Pfizer Investigational Site
  • Spanien
      • A Coruña, Spanien, 15006
        • Pfizer Investigational Site
      • Madrid, Spanien, 28046
        • Pfizer Investigational Site
      • Malaga, Spanien, 29009
        • Pfizer Investigational Site
      • Sevilla, Spanien, 41013
        • Pfizer Investigational Site
    • A Coruña
      • Santiago de Compostela, A Coruña, Spanien, 15705
        • Pfizer Investigational Site
  • Sverige
      • Falun, Sverige, 791 82
        • Pfizer Investigational Site
      • Goteborg, Sverige, 413 46
        • Pfizer Investigational Site
      • Uppsala, Sverige, 751 85
        • Pfizer Investigational Site
  • Thailand
    • Bangkok
      • Rajathevee, Bangkok, Thailand, 10400
        • Pfizer Investigational Site
    • Chiang Mai
      • Amphoe Muang, Chiang Mai, Thailand, 50200
        • Pfizer Investigational Site
    • Khonkaen
      • Muang District, Khonkaen, Thailand, 40002
        • Pfizer Investigational Site
  • Tyskland
      • Berlin, Tyskland, 14059
        • Pfizer Investigational Site
      • Dresden, Tyskland, 01067
        • Pfizer Investigational Site
      • Hamburg, Tyskland, 22081
        • Pfizer Investigational Site
      • Leipzig, Tyskland, 04103
        • Pfizer Investigational Site
      • Nuernberg, Tyskland, 90429
        • Pfizer Investigational Site
      • Rheine, Tyskland, 48431
        • Pfizer Investigational Site
  • Venezuela
    • DC/ Municipio Libertados
      • Caracas, DC/ Municipio Libertados, Venezuela, 1040-A
        • Pfizer Investigational Site
    • Distrito Capital
      • Caracas, Distrito Capital, Venezuela, 1010
        • Pfizer Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • The patient has a diagnosis of Rheumatoid Arthritis based on the American College of Rheumatology (ACR) 1987 Revised Criteria.
  • The patient has active disease as defined by both >=4 tender or painful joints on motion and >= 4 joints swollen; and either an erythrocyte sedimentation rate (ESR) > 28 mm or a C-reactive protein (CRP) concentration > 7 mg/dL.
  • Patient had an inadequate response to at least one disease modifying antirheumatic drug (traditional or biologic) due to lack of efficacy or toxicity.
  • Patient must remain on at least one background traditional disease modifying antirheumatic drug.
  • No evidence of inadequately treated latent or active infection with Mycobacterium tuberculosis.

Exclusion Criteria:

  • Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White blood cell count <3.0 x 109/L; Absolute neutrophil count <1.2 x 109/L; Platelet count <100 x 109/L.
  • History of any other rheumatic autoimmune disease other than Sjogren's syndrome.
  • No malignancy or history of malignancy.
  • History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Aktiv 10 mg
Medicin: CP-690,550
Film coated tablet, 5 mg PO BID, 1 year
Medicin: CP-690,550
Film coated tablet, 10 mg PO BID, 1 year
Eksperimentel: Active 5 mg
Medicin: CP-690,550
Film coated tablet, 5 mg PO BID, 1 year
Medicin: CP-690,550
Film coated tablet, 10 mg PO BID, 1 year
Placebo komparator: Placebo Sequence 1
Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
Medicin: Placebo
Film coated tablet, 1 tablet PO BID, 3-6 months
Placebo komparator: Placebo Sequence 2
Placebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.
Medicin: Placebo
Film coated tablet, 1 tablet PO BID, 3-6 months

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring fra baseline i Health Assessment Questionnaire-Disability Index (HAQ-DI) score på måned 3
Tidsramme: Baseline, måned 3
HAQ-DI: deltagerrapporteret vurdering af evnen til at udføre opgaver i 8 kategorier af daglige aktiviteter: påklædning/brudgom;opstå;spise; gå; nå; greb; hygiejne; almindelige aktiviteter i den seneste uge. Hvert punkt scorede på en 4-punkts skala fra 0-3:0=ingen besvær;1=nogle besvær;2=meget besvær;3=ikke i stand til at gøre. Samlet score blev beregnet som summen af ​​domænescores og divideret med antallet af besvarede domæner. Samlet mulig scoreområde 0-3:0 = mindste sværhedsgrad og 3 = ekstrem sværhedsgrad. Til sammenligning af CP-690.550 med placebo blev placebosekvenser kombineret i en enkelt rapporteringsgruppe til måned 3-analyse.
Baseline, måned 3
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6
Tidsramme: Month 6
ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count (TJC); >= 20% improvement in swollen joint count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.
Month 6
Percentage of Participants Achieving Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])Less Than 2.6 at Month 6
Tidsramme: Month 6
DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, erythrocyte sedimentation rate (ESR) (millimeters/hour[mm/hour]) and patient's global assessment (PtGA) of disease activity(participant rated arthritis activity assessment). Total score range:0-9.4, higher score=more disease activity. DAS28-4 (ESR) less than or equal to (<=)3.2 implied low disease activity, greater than (>)3.2 to 5.1 implied moderate to high disease activity, less than (<)2.6=remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.
Month 6

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Sygdomsaktivitetsscore ved hjælp af 28-ledstælling og C-reaktivt protein (3 variabler) (DAS28-3 [CRP]) i måned 9 og 12
Tidsramme: Måned 9, 12
DAS28-3 (CRP) blev beregnet ud fra SJC og TJC ved hjælp af 28 ledtal og CRP (mg/L). Samlet scoreområde: 0 til 9,4, højere score indikerede mere sygdomsaktivitet. DAS28-3 (CRP) =<3,2 antydede lav sygdomsaktivitet, >3,2 til 5,1 antydede moderat til høj sygdomsaktivitet og <2,6 antydede remission.
Måned 9, 12
Patientvurdering af gigtsmerter ved 9. og 12. måned
Tidsramme: Måned 9, 12
Deltagerne bedømte sværhedsgraden af ​​gigtsmerter på en 0 til 100 mm VAS, hvor 0 mm = ingen smerte og 100 mm = den mest alvorlige smerte.
Måned 9, 12
Antal hændelser, inklusive besøg, operationer, tests eller anordninger som vurderet ved hjælp af RA-HCRU ved baseline, måned 3 og 6
Tidsramme: Baseline, måned 3, 6
RA-HCRU vurderede brugen af ​​sundhedsydelser i de foregående 3 måneder for direkte eller indirekte medicinske omkostningsdomæner. Ethvert RA/ikke-RA-relateret antal hændelser, herunder besøg hos læge, ikke-læge, ER-behandling på hospital, indlæggelser, antal operationer, diagnostiske tests og anvendte anordninger/hjælpemidler blev rapporteret.
Baseline, måned 3, 6
Antal hændelser, inklusive besøg, operationer, tests eller anordninger som vurderet ved hjælp af RA-HCRU på måned 12
Tidsramme: Måned 12
RA-HCRU vurderede brugen af ​​sundhedsydelser i de foregående 3 måneder for direkte eller indirekte medicinske omkostningsdomæner. Ethvert antal RA/ikke-RA-relaterede hændelser, herunder besøg hos læge, ikke-læge, ER-behandling på hospital, indlæggelser, antal operationer, diagnostiske tests og anvendte anordninger/hjælpemidler blev rapporteret.
Måned 12
36-punkts kortformssundhedsundersøgelse (SF-36) ved baseline, måned 1, 3 og 6
Tidsramme: Baseline, måned 1, 3, 6
SF-36 er en standardiseret undersøgelse, der evaluerer 8 aspekter af funktionel sundhed og velvære: fysisk funktion, rolle fysisk, kropslig smerte, generel sundhed, vitalitet, social funktion, rolle følelsesmæssig og mental sundhed. Scoren for et afsnit er et gennemsnit af de enkelte spørgsmålsscores, som skaleres 0-100 (100=højeste funktionsniveau) og indberettes som 2 opsummerende scores; fysisk komponentscore og mental komponentscore. Samlet scoreinterval for de sammenfattende scores = 0-100, hvor højere score repræsenterer højere funktionsniveau.
Baseline, måned 1, 3, 6
Medical Outcomes Study Sleep Scale (MOS-SS) ved baseline, måned 1, 3 og 6
Tidsramme: Baseline, måned 1, 3, 6
Deltager-vurderet spørgeskema med 12 elementer til vurdering af søvnkonstruktioner i løbet af den seneste uge.7 underskalaer: søvnforstyrrelser, snorken, vågnet åndenød, søvntilstrækkelighed, somnolens (interval:0-100); søvnmængde(interval:0-24), optimal søvn(ja eller nej). 9 punkters indeksmålinger af søvnforstyrrelser giver sammensatte resultater: oversigt over søvnproblemer, overordnet søvnproblem. Undtagen Tilstrækkelighed, Optimal, Søvnmængde, højere score=mere svækkelse. Score transformeret(faktisk råscore(RS) minus lavest mulige score divideret med muligt RS-område*100);totalscoreinterval:0-100,højere score=mere intensitet af egenskab.
Baseline, måned 1, 3, 6
Antal deltagere med optimal søvn vurderet ved hjælp af medicinske resultater Undersøg søvnskala (MOS-SS) ved baseline, måned 1, 3 og 6
Tidsramme: Baseline, måned 1, 3, 6
MOS-SS: deltager-vurderet 12-punkts spørgeskema til vurdering af søvnkonstruktioner over den seneste uge. Det omfattede 7 underskalaer: søvnforstyrrelser, snorken, vækket åndenød, søvntilstrækkelighed, somnolens, søvnmængde og optimal søvn. Deltagerne svarede, om deres søvn var optimal eller ej, ved at vælge ja eller nej. Antal deltagere med optimal søvn oplyses.
Baseline, måned 1, 3, 6
Funktionel vurdering af kronisk sygdomsterapi (FACIT)-træthedsskala ved baseline, måned 1, 3 og 6
Tidsramme: Baseline, måned 1, 3, 6
FACIT-Fatigue er et spørgeskema med 13 punkter. Deltageren scorede hvert punkt på en 5-trins skala: 0 (slet ikke) til 4 (meget meget). Jo større deltagerens svar på spørgsmålene (med undtagelse af 2 negativt angivet), jo større træthed. For alle spørgsmål, bortset fra de 2 negativt anførte, blev koden omvendt, og en ny score blev beregnet til 4 minus deltagerens svar. Summen af ​​alle svar resulterede i FACIT-træthedsscore for en samlet mulig score på 0 (dårlig score) til 52 (bedre score). En højere score afspejlede en forbedring af deltagerens helbredstilstand.
Baseline, måned 1, 3, 6
Euro Quality of Life (EQ-5D) - Health State Profile Utility Score ved baseline, måned 3 og 6
Tidsramme: Baseline, måned 3, 6
EQ-5D: deltagerbedømt spørgeskema til vurdering af sundhedsrelateret livskvalitet i form af en enkelt nyttescore. Health State Profile-komponenten vurderer niveauet af det nuværende helbred for 5 domæner: mobilitet, egenomsorg, sædvanlige aktiviteter, smerte og ubehag samt angst og depression; 1 indikerer bedre helbredstilstand (ingen problemer); 3 angiver den værste helbredstilstand ("sengbundet"). Scoreformel udviklet af EuroQol Group tildeler en nytteværdi for hvert domæne i profilen. Score transformeres og resulterer i et samlet scoreområde -0,594 til 1,000; højere score indikerer en bedre helbredstilstand.
Baseline, måned 3, 6
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Week 2, Month 1, 2, 3, 4.5 and 6
Tidsramme: Week 2, Month 1, 2, 3, 4.5, 6
ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Week 2, Month 1, 2, 3, 4.5, 6
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) at Month 9 and 12
Tidsramme: Month 9, 12
ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Month 9, 12
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Week 2, Month 1, 2, 3, 4.5 and 6
Tidsramme: Week 2, Month 1, 2, 3, 4.5, 6
ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Week 2, Month 1, 2, 3, 4.5, 6
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) at Month 9 and 12
Tidsramme: Month 9, 12
ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Month 9, 12
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Week 2, Month 1, 2, 3, 4.5 and 6
Tidsramme: Week 2, Month 1, 2, 3, 4.5, 6
ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Week 2, Month 1, 2, 3, 4.5, 6
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) at Month 9 and 12
Tidsramme: Month 9, 12
ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of HAQ); and CRP.
Month 9, 12
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6
Tidsramme: Week 2, Month 1, 2, 3, 4.5, 6
DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.
Week 2, Month 1, 2, 3, 4.5, 6
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 3 and 6
Tidsramme: Baseline, Month 3, 6
DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.
Baseline, Month 3, 6
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 12
Tidsramme: Month 12
DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =<3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.
Month 12
Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])
Tidsramme: Baseline, Week 2, Month 1, 2, 3, 4.5, 6, 9, 12
DAS28-4 (CRP) was calculated from SJC and TJC using the 28 joints count, CRP [mg/L] and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 [CRP] <=3.2 implied low disease activity, DAS28-4 [CRP] >3.2 to 5.1 implied moderate to high disease activity and DAS28 <2.6 implied remission.
Baseline, Week 2, Month 1, 2, 3, 4.5, 6, 9, 12
Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])
Tidsramme: Baseline, Month 3, 6, 12
DAS28-3 (ESR) was calculated from the number of SJC and TJC using the 28 joints count and ESR (mm/hr). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) <=3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity and <2.6 implied remission.
Baseline, Month 3, 6, 12
Health Assessment Questionnaire Disability Index (HAQ-DI) at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6
Tidsramme: Baseline, Week 2, Month 1, 2, 3, 4.5, 6
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.
Baseline, Week 2, Month 1, 2, 3, 4.5, 6
Health Assessment Questionnaire Disability Index (HAQ-DI) at Month 9 and 12
Tidsramme: Month 9, Month 12
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0=least difficulty and 3=extreme difficulty.
Month 9, Month 12
Patient Assessment of Arthritis Pain at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6
Tidsramme: Baseline, Week 2, Month 1, 2, 3, 4.5, 6
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Baseline, Week 2, Month 1, 2, 3, 4.5, 6
Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6
Tidsramme: Baseline, Week 2, Month 1, 2, 3, 4.5, 6
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.
Baseline, Week 2, Month 1, 2, 3, 4.5, 6
Patient Global Assessment (PtGA) of Arthritis Pain at Month 9 and 12
Tidsramme: Month 9, 12
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.
Month 9, 12
Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Week 2, Month 1, 2, 3, 4.5 and 6
Tidsramme: Baseline, Week 2, Month 1, 2, 3, 4.5, 6
Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Baseline, Week 2, Month 1, 2, 3, 4.5, 6
Physician Global Assessment (PGA) of Arthritis at Month 9 and 12
Tidsramme: Month 9, 12
Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Month 9, 12
36-Item Short-Form Health Survey (SF-36) at Month 9 and 12
Tidsramme: Month 9, 12
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and is reported as 2 summary scores; physical component score and mental component score. Total score range for the summary scores = 0-100, where higher score represents higher level of functioning.
Month 9, 12
Medical Outcome Study (MOS) Sleep Scale at Month 12
Tidsramme: Month 12
Participant-rated 12 item questionnaire to assess constructs of sleep over past week.7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity(range:0-24), optimal sleep(yes or no). 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except Adequacy, Optimal, Quantity of sleep, higher scores=more impairment. Scores transformed(actual raw score(RS) minus lowest possible score divided by possible RS range*100);total score range:0-100,higher score=more intensity of attribute.
Month 12
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study Sleep Scale (MOS-SS) at Month 12
Tidsramme: Month 12
MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.
Month 12
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Month 12
Tidsramme: Month 12
FACIT-Fatigue is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Month 12
Euro Quality of Life (EQ-5D)- Health State Profile Utility Score at Month 12
Tidsramme: Month 12
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Month 12
Work Limitations Questionnaire (WLQ) Score at Baseline, Month 3 and 6
Tidsramme: Baseline, Month 3, 6
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: time management scale (5-items); physical demands scale (6-item); mental-interpersonal demands Scale (9-items); output demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work loss index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).
Baseline, Month 3, 6
Work Limitations Questionnaire (WLQ) Score at Month 12
Tidsramme: Month 12
WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: time management scale (5-items); physical demands scale (6-item); mental-interpersonal demands scale (9-items); output demands scale (5-items). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work loss index, which represented percentage of lost work over time period relative to a normative population, was derived (total score:0[no loss] to 100[complete loss of work]).
Month 12
Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6
Tidsramme: Baseline, Month 3, 6
Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor, non-medical practitioner, nursing home, hospital, surgery, emergency room(ER) treatment, diagnostic tests, over-night stay, home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status, willingness to work, work disability due to RA, sick leave,part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.
Baseline, Month 3, 6
Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12
Tidsramme: Month 12
Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost:visit to doctor,non-medical practitioner,nursing home,hospital,surgery,emergency room(ER) treatment,diagnostic tests, over-night stay,home healthcare services, aids/devices used. Indirect costs associated with functional disability:employment status,willingness to work,work disability due to RA,sick leave,part time work,ability to perform chores,chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale;higher score=higher medical cost.
Month 12
Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6
Tidsramme: Baseline, Month 3, 6
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.
Baseline, Month 3, 6
Number of Days as Assessed Using RA-HCRU at Month 12
Tidsramme: Month 12
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains.Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.
Month 12
Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6
Tidsramme: Baseline, Month 3, 6
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.
Baseline, Month 3, 6
Number of Hours Per Day as Assessed RA-HCRU at Month 12
Tidsramme: Month 12
RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, work done and work missed were reported.
Month 12
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6
Tidsramme: Baseline, Month 3, 6
Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.
Baseline, Month 3, 6
Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12
Tidsramme: Month 12
Work performance of participants on number of days bothered was based on a 0 to 10-point scale, where higher score indicated lower work performance.
Month 12

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Global Assessment of Arthritis
Tidsramme: 2 weeks
Patient global assessment of arthritis: participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS where 0 = very well and 100 = very poorly.
2 weeks
Time to First Greater Than 1 Day Sequential Decrease in Pain From Baseline for Patient Assessment of Arthritis Pain
Tidsramme: 2 weeks
Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
2 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Pfizer

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2009

Primær færdiggørelse (Faktiske)

1. januar 2011

Studieafslutning (Faktiske)

1. januar 2011

Datoer for studieregistrering

Først indsendt

3. marts 2009

Først indsendt, der opfyldte QC-kriterier

3. marts 2009

Først opslået (Skøn)

5. marts 2009

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

10. januar 2013

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. december 2012

Sidst verificeret

1. december 2012

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • A3921046

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner